Technology
Health
Medical
CorMedix
$7.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.08 (-1.13%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell CorMedix and other stocks, options, ETFs, and crypto commission-free!
About
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Read More The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Employees
22
Headquarters
Berkeley Heights, New Jersey
Founded
2006
Market Cap
168.59M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
654.30K
High Today
$7.09
Low Today
$6.80
Open Price
$7.07
Volume
140.66K
52 Week High
$13.70
52 Week Low
$0.875
Collections
Technology
Health
Medical
Pharmaceutical
US
North America
News
Seeking AlphaMay 13
CorMedix, Inc. CEO Khoso Baluch on Q1 2019 Results - Earnings Call Transcript
CorMedix, Inc. (NYSEMKT:CRMD) Q1 2019 Results Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Dan Ferry - IR-LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Phoebe Mounts - EVP and General Counsel Paul Chew - Chief Medical Officer Conference Call Participants Operator Greetings. Welcome to CorMedix's First Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded. I would now like to turn the conference over to your host M...
Yahoo FinanceMay 13
CorMedix Reports Q1 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 13
CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business events. Recent Corporate and Clinical Highlights: Announced that the...
Price Paid on Robinhood
237% Higher
Right Now
52 Week Low
$0.875
Average Price Paid
$2.08
52 Week High
$13.70
Earnings
-$0.28
-$0.18
-$0.08
$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.28 per share
Actual
-$0.22 per share